Corvus Pharmaceuticals, Inc.
CRVS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $8,454 | $7,873 | $7,453 | $5,974 |
| G&A Expenses | $2,118 | $2,387 | $2,469 | $2,131 |
| SG&A Expenses | $2,118 | $2,387 | $2,469 | $2,131 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $10,572 | $10,260 | $9,922 | $8,105 |
| Operating Income | -$10,572 | -$10,260 | -$9,922 | -$8,105 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $415 | $2,262 | $25,115 | -$4,008 |
| Pre-Tax Income | -$10,157 | -$7,998 | $15,193 | -$12,113 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$10,157 | -$7,998 | $15,193 | -$12,113 |
| % Margin | – | – | – | – |
| EPS | -0.12 | -0.1 | 0.21 | -0.18 |
| % Growth | -20% | -147.6% | 216.7% | – |
| EPS Diluted | -0.12 | -0.1 | -0.13 | -0.18 |
| Weighted Avg Shares Out | 82,836 | 77,774 | 72,126 | 68,347 |
| Weighted Avg Shares Out Dil | 82,836 | 77,774 | 75,153 | 68,347 |
| Supplemental Information | – | – | – | – |
| Interest Income | $738 | $639 | $525 | $508 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $28 | $29 | $22 | $20 |
| EBITDA | -$10,129 | -$10,231 | -$9,900 | -$8,085 |
| % Margin | – | – | – | – |